Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,762
datasets available to search
ShareScore release 0.9.0
Dataset results
3,762 results for “Combination treatment”
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
ClinicalTrials.gov study NCT03200847. IPD Sharing: NO. Countries: 1. Publications: 1.
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
ClinicalTrials.gov study NCT01556425. IPD Sharing: NO. Countries: 1. Publications: 1.
Selecting Effective Combinations of Treatment for Low Back Pain
ClinicalTrials.gov study NCT03520387. IPD Sharing: YES. Countries: 1. Publications: 1.
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
ClinicalTrials.gov study NCT01289821. IPD Sharing: Not stated. Countries: 7. Publications: 1.
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
ClinicalTrials.gov study NCT00094653. IPD Sharing: Not stated. Countries: 13. Publications: 10.
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
ClinicalTrials.gov study NCT03829410. IPD Sharing: NO. Countries: 1. Publications: 3.
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)
ClinicalTrials.gov study NCT04736485. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
ClinicalTrials.gov study NCT05116202. IPD Sharing: YES. Countries: 5. Publications: 1.
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
ClinicalTrials.gov study NCT03880019. IPD Sharing: YES. Countries: 1. Publications: 2.
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
ClinicalTrials.gov study NCT01768286. IPD Sharing: YES. Countries: 1. Publications: 2.
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
ClinicalTrials.gov study NCT01330316. IPD Sharing: Not stated. Countries: 15. Publications: 1.
Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
ClinicalTrials.gov study NCT00210106. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
ClinicalTrials.gov study NCT00090103. IPD Sharing: Not stated. Countries: 36. Publications: 14.
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
ClinicalTrials.gov study NCT00903682. IPD Sharing: Not stated. Countries: 11. Publications: 3.
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
ClinicalTrials.gov study NCT02300103. IPD Sharing: YES. Countries: 4. Publications: 0.
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-
ClinicalTrials.gov study NCT01663727. IPD Sharing: Not stated. Countries: 16. Publications: 2.
Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris
ClinicalTrials.gov study NCT02431494. IPD Sharing: NO. Countries: 1. Publications: 8.
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
ClinicalTrials.gov study NCT02599402. IPD Sharing: Not stated. Countries: 12. Publications: 1.
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lym
ClinicalTrials.gov study NCT03462719. IPD Sharing: Not stated. Countries: 14. Publications: 3.
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
ClinicalTrials.gov study NCT01045707. IPD Sharing: Not stated. Countries: 9. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.